PharmaVoice

article thumbnail

On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst

PharmaVoice

Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.

147
147
article thumbnail

With compounders out of the way, Lilly and Novo go after each other

PharmaVoice

The two obesity leaders are pulling on all levers to stay on top of the market.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

After an up and down year, pharma’s R&D landscape is shifting again

PharmaVoice

While clinical trial funding was up, deal-making was down, and new uncertainties are coming into the picture.

100
100
article thumbnail

J&J scores FDA OK for immune drug touted as future blockbuster

PharmaVoice

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in annual sales at its peak.

article thumbnail

Can real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.

PharmaVoice

Turmoil at the NIH has led to handwringing among researchers and drugmakers who rely on public funding.

130
130
article thumbnail

Is the FDA headed for a major reorganization?

PharmaVoice

A leaked document revealed details about changes that could impact how the agency operates, but recent comments from FDA Commissioner Dr. Marty Makary have muddied the picture.

FDA 147
article thumbnail

US backlash against mRNA vaccines could hinder scientific progress

PharmaVoice

U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and scientific advancements.

Vaccines 257